Symbols / MGTX
MGTX Chart
About
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 633.87M |
| Enterprise Value | 693.00M | Income | -168.69M | Sales | 27.42M |
| Book/sh | -0.50 | Cash/sh | 0.18 | Dividend Yield | — |
| Payout | 0.00% | Employees | 409 | IPO | — |
| P/E | — | Forward P/E | -3.14 | PEG | — |
| P/S | 23.12 | P/B | -15.62 | P/C | — |
| EV/EBITDA | -4.58 | EV/Sales | 25.28 | Quick Ratio | 0.17 |
| Current Ratio | 0.22 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.11 | EPS next Y | -2.51 | EPS Growth | — |
| Revenue Growth | -96.20% | Earnings | 2026-03-12 | ROA | -41.91% |
| ROE | -6.11% | ROIC | — | Gross Margin | 41.01% |
| Oper. Margin | -112.32% | Profit Margin | 0.00% | Shs Outstand | 80.49M |
| Shs Float | 41.37M | Short Float | 10.50% | Short Ratio | 13.07 |
| Short Interest | — | 52W High | 9.73 | 52W Low | 4.55 |
| Beta | 1.38 | Avg Volume | 472.11K | Volume | 95.11K |
| Target Price | $26.75 | Recom | None | Prev Close | $7.70 |
| Price | $7.88 | Change | 2.27% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$26.75
Mean price target
2. Current target
$7.88
Latest analyst target
3. DCF / Fair value
$-13.61
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.88
Low
$14.00
High
$50.00
Mean
$26.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-24 | init | HC Wainwright & Co. | — → Buy | $20 |
| 2025-11-14 | main | RBC Capital | Outperform → Outperform | $16 |
| 2025-11-14 | main | Chardan Capital | Buy → Buy | $35 |
| 2025-11-11 | main | Piper Sandler | Overweight → Overweight | $30 |
| 2025-11-11 | main | Chardan Capital | Buy → Buy | $35 |
| 2025-10-21 | init | Raymond James | — → Strong Buy | $29 |
| 2025-08-15 | main | Chardan Capital | Buy → Buy | $35 |
| 2025-05-14 | main | Chardan Capital | Buy → Buy | $35 |
| 2025-03-17 | main | RBC Capital | Outperform → Outperform | $13 |
| 2025-02-24 | main | Chardan Capital | Buy → Buy | $36 |
| 2024-11-18 | main | Chardan Capital | Buy → Buy | $36 |
| 2024-11-14 | main | RBC Capital | Outperform → Outperform | $11 |
| 2024-08-13 | main | RBC Capital | Outperform → Outperform | $9 |
| 2024-07-31 | main | Chardan Capital | Buy → Buy | $36 |
| 2024-03-15 | reit | RBC Capital | Outperform → Outperform | $11 |
| 2023-08-11 | main | RBC Capital | Outperform → Outperform | $11 |
| 2023-08-11 | reit | Chardan Capital | Buy → Buy | $41 |
| 2023-05-12 | main | Piper Sandler | Overweight → Overweight | $25 |
| 2023-03-16 | main | Chardan Capital | — → Buy | $41 |
| 2023-03-15 | main | RBC Capital | — → Outperform | $22 |
- MeiraGTx Holdings plc (NASDAQ:MGTX) has caught the attention of institutional investors who hold a sizeable 31% stake - Yahoo Finance ue, 16 Dec 2025 08
- (MGTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily hu, 19 Feb 2026 13
- $MGTX stock is up 12% today. Here's what we see in our data. - Quiver Quantitative ue, 21 Oct 2025 07
- Analysts Have Lowered Expectations For MeiraGTx Holdings plc (NASDAQ:MGTX) After Its Latest Results - simplywall.st Mon, 17 Nov 2025 08
- MeiraGTx Holdings plc (MGTX) Stock Analysis: A Biotech Gem with a 247.85% Upside Potential - DirectorsTalk Interviews Fri, 16 Jan 2026 08
- MeiraGTx stock soars after Eli Lilly partnership on eye disease therapies - Investing.com Mon, 10 Nov 2025 08
- MeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy Vital - Seeking Alpha hu, 25 Sep 2025 07
- MGTX Stock Soared 13% Today – What’s The Eli Lilly Angle? - Stocktwits Mon, 10 Nov 2025 08
- MeiraGTx (MGTX) Moves 12.4% Higher: Will This Strength Last? - Yahoo Finance Wed, 22 Oct 2025 07
- MeiraGTx (MGTX) Announces $18.2M Share Purchase Agreement - GuruFocus Fri, 02 Jan 2026 08
- Responsive Playbooks and the MGTX Inflection - Stock Traders Daily Sun, 08 Feb 2026 12
- MeiraGTx inks $18.2M share purchase deal with Perceptive Advisors - Seeking Alpha Fri, 02 Jan 2026 08
- MeiraGTx Holdings plc Enters Strategic Collaboration with Eli Lilly to Advance Gene Therapy in Ophthalmology and Reports Q3 2025 Financial Results - Quiver Quantitative hu, 13 Nov 2025 08
- MeiraGTx stock price target raised to $30 by Piper Sandler on Eli Lilly deal - Investing.com ue, 11 Nov 2025 08
- MeiraGTx Holdings (NASDAQ:MGTX) Is Making Moderate Use Of Debt - simplywall.st Wed, 22 Oct 2025 07
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 62500 | — | — | FORBES ALEXANDRIA | Chief Executive Officer | — | 2026-02-20 00:00:00 | D | nan |
| 1 | 7500 | — | — | ZELDIN ROBERT K | Officer | — | 2026-02-20 00:00:00 | D | nan |
| 2 | 60000 | — | — | GIROUX RICHARD | Chief Operating Officer | — | 2026-02-20 00:00:00 | D | nan |
| 3 | 25000 | — | — | NAYLOR STUART | Officer | — | 2026-02-20 00:00:00 | D | nan |
| 4 | 11250 | — | — | WOLLIN ROBERT J | General Counsel | — | 2026-02-20 00:00:00 | D | nan |
| 5 | 310000 | — | — | FORBES ALEXANDRIA | Chief Executive Officer | — | 2026-01-16 00:00:00 | D | nan |
| 6 | 35000 | — | — | ZELDIN ROBERT K | Officer | — | 2026-01-16 00:00:00 | D | nan |
| 7 | 310000 | — | — | GIROUX RICHARD | Chief Operating Officer | — | 2026-01-16 00:00:00 | D | nan |
| 8 | 75000 | — | — | NAYLOR STUART | Officer | — | 2026-01-16 00:00:00 | D | nan |
| 9 | 50000 | — | — | WOLLIN ROBERT J | General Counsel | — | 2026-01-16 00:00:00 | D | nan |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -147.39M | -120.57M | -106.97M | -64.67M |
| TotalUnusualItems | 25.55M | 63.51M | -9.09M | -6.73M |
| TotalUnusualItemsExcludingGoodwill | 25.55M | 63.51M | -9.09M | -6.73M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -147.79M | -84.03M | -129.62M | -79.56M |
| ReconciledDepreciation | 12.68M | 13.72M | 8.60M | 7.87M |
| ReconciledCostOfRevenue | 23.79M | 0.00 | ||
| EBITDA | -121.84M | -57.06M | -116.07M | -71.40M |
| EBIT | -134.52M | -70.78M | -124.67M | -79.27M |
| NetInterestIncome | -9.13M | -10.97M | -4.17M | -76.00K |
| InterestExpense | 13.27M | 13.24M | 4.95M | 288.00K |
| InterestIncome | 4.14M | 2.27M | 777.00K | 212.00K |
| NormalizedIncome | -173.34M | -147.53M | -120.52M | -72.83M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -147.79M | -84.03M | -129.62M | -79.56M |
| TotalExpenses | 197.49M | 151.08M | 132.28M | 110.46M |
| TotalOperatingIncomeAsReported | -164.21M | -137.06M | -116.36M | -72.76M |
| DilutedAverageShares | 69.82M | 56.49M | 45.18M | 44.14M |
| BasicAverageShares | 69.82M | 56.49M | 45.18M | 44.14M |
| DilutedEPS | -2.12 | -1.49 | -2.87 | -1.80 |
| BasicEPS | -2.12 | -1.49 | -2.87 | -1.80 |
| DilutedNIAvailtoComStockholders | -147.79M | -84.03M | -129.62M | -79.56M |
| NetIncomeCommonStockholders | -147.79M | -84.03M | -129.62M | -79.56M |
| NetIncome | -147.79M | -84.03M | -129.62M | -79.56M |
| NetIncomeIncludingNoncontrollingInterests | -147.79M | -84.03M | -129.62M | -79.56M |
| NetIncomeContinuousOperations | -147.79M | -84.03M | -129.62M | -79.56M |
| PretaxIncome | -147.79M | -84.03M | -129.62M | -79.56M |
| OtherIncomeExpense | 25.55M | 64.01M | -9.09M | -6.73M |
| OtherNonOperatingIncomeExpenses | 499.00K | 361.00K | -434.00K | |
| SpecialIncomeCharges | 28.43M | 54.21M | 0.00 | |
| GainOnSaleOfPPE | 28.43M | 54.21M | 0.00 | |
| GainOnSaleOfSecurity | -2.89M | 9.30M | -9.09M | -6.73M |
| NetNonOperatingInterestIncomeExpense | -9.13M | -10.97M | -4.17M | -76.00K |
| InterestExpenseNonOperating | 13.27M | 13.24M | 4.95M | 288.00K |
| InterestIncomeNonOperating | 4.14M | 2.27M | 777.00K | 212.00K |
| OperatingIncome | -164.21M | -137.06M | -116.36M | -72.76M |
| OperatingExpense | 173.70M | 151.08M | 132.28M | 110.46M |
| ResearchAndDevelopment | 119.48M | 103.78M | 85.72M | 66.69M |
| SellingGeneralAndAdministration | 54.22M | 47.29M | 46.55M | 43.77M |
| GeneralAndAdministrativeExpense | 54.22M | 47.29M | 46.55M | 43.77M |
| OtherGandA | 54.22M | 47.29M | 46.55M | 43.77M |
| GrossProfit | 9.49M | 14.02M | ||
| CostOfRevenue | 23.79M | 0.00 | ||
| TotalRevenue | 33.28M | 14.02M | 15.92M | 37.70M |
| OperatingRevenue | 33.28M | 14.02M | 15.92M | 37.70M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 78.40M | 63.60M | 48.48M | 44.55M |
| ShareIssued | 78.40M | 63.60M | 48.48M | 44.55M |
| TotalDebt | 84.80M | 89.26M | 92.25M | 23.73M |
| TangibleBookValue | 67.01M | 137.06M | 115.66M | 182.83M |
| InvestedCapital | 141.05M | 210.30M | 188.77M | 185.40M |
| WorkingCapital | 62.73M | 92.54M | 72.27M | 115.11M |
| NetTangibleAssets | 67.01M | 137.06M | 115.66M | 182.83M |
| CapitalLeaseObligations | 11.58M | 17.14M | 21.21M | 23.73M |
| CommonStockEquity | 67.83M | 138.18M | 117.74M | 185.40M |
| TotalCapitalization | 141.05M | 210.30M | 188.77M | 185.40M |
| TotalEquityGrossMinorityInterest | 67.83M | 138.18M | 117.74M | 185.40M |
| StockholdersEquity | 67.83M | 138.18M | 117.74M | 185.40M |
| GainsLossesNotAffectingRetainedEarnings | -3.72M | -1.44M | 6.05M | -2.67M |
| OtherEquityAdjustments | -3.72M | -1.44M | 6.05M | -2.67M |
| RetainedEarnings | -702.02M | -554.23M | -470.20M | -340.59M |
| AdditionalPaidInCapital | 773.57M | 693.84M | 581.89M | 528.66M |
| CapitalStock | 3.00K | 2.00K | 2.00K | 2.00K |
| CommonStock | 3.00K | 2.00K | 2.00K | 2.00K |
| TotalLiabilitiesNetMinorityInterest | 201.92M | 188.57M | 200.50M | 134.76M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 141.14M | 121.49M | 118.43M | 66.64M |
| OtherNonCurrentLiabilities | 262.00K | 953.00K | ||
| NonCurrentDeferredLiabilities | 57.58M | 34.02M | 27.62M | 43.24M |
| NonCurrentDeferredRevenue | 57.58M | 34.02M | 27.44M | 43.05M |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 186.00K | 196.00K | |
| LongTermDebtAndCapitalLeaseObligation | 80.74M | 85.07M | 88.36M | 20.36M |
| LongTermCapitalLeaseObligation | 7.52M | 12.95M | 17.33M | 20.36M |
| LongTermDebt | 73.22M | 72.12M | 71.03M | |
| LongTermProvisions | 2.82M | 2.40M | 2.18M | 2.08M |
| CurrentLiabilities | 60.78M | 67.08M | 82.07M | 68.13M |
| OtherCurrentLiabilities | 903.00K | 1.28M | 6.63M | |
| CurrentDeferredLiabilities | 4.83M | 2.93M | 15.12M | 21.82M |
| CurrentDeferredRevenue | 4.83M | 2.93M | 15.12M | 21.82M |
| CurrentDebtAndCapitalLeaseObligation | 4.05M | 4.19M | 3.88M | 3.37M |
| CurrentCapitalLeaseObligation | 4.05M | 4.19M | 3.88M | 3.37M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 11.20M | 12.13M | 9.60M | 6.03M |
| PayablesAndAccruedExpenses | 39.80M | 46.55M | 46.83M | 36.91M |
| CurrentAccruedExpenses | 16.22M | 30.51M | 30.22M | 21.56M |
| InterestPayable | 0.00 | 2.94M | 0.00 | |
| Payables | 23.59M | 16.04M | 16.62M | 15.35M |
| AccountsPayable | 23.59M | 16.04M | 16.62M | 15.35M |
| TotalAssets | 269.75M | 326.74M | 318.24M | 320.16M |
| TotalNonCurrentAssets | 146.23M | 167.12M | 163.90M | 136.92M |
| OtherNonCurrentAssets | 3.01M | 3.00M | 1.40M | 1.40M |
| InvestmentsAndAdvances | 6.75M | 6.77M | 6.33M | 6.66M |
| LongTermEquityInvestment | 6.75M | 6.77M | 6.33M | 6.66M |
| GoodwillAndOtherIntangibleAssets | 821.00K | 1.12M | 2.08M | 2.57M |
| OtherIntangibleAssets | 821.00K | 1.12M | 2.08M | 2.57M |
| NetPPE | 135.65M | 156.24M | 154.09M | 126.29M |
| AccumulatedDepreciation | -42.30M | -33.33M | -20.39M | -14.48M |
| GrossPPE | 177.96M | 189.56M | 174.49M | 140.77M |
| Leases | 99.37M | 103.08M | 91.05M | 60.88M |
| OtherProperties | 70.53M | 78.38M | 76.00M | 73.45M |
| MachineryFurnitureEquipment | 8.05M | 8.10M | 7.43M | 6.44M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 123.52M | 159.62M | 154.34M | 183.24M |
| OtherCurrentAssets | 2.02M | 1.02M | 1.67M | 2.42M |
| PrepaidAssets | 6.83M | 5.62M | 8.13M | 8.10M |
| Inventory | 385.00K | 0.00 | ||
| Receivables | 10.63M | 23.41M | 29.02M | 35.02M |
| OtherReceivables | 950.00K | |||
| TaxesReceivable | 8.97M | 13.28M | 7.69M | 12.63M |
| AccountsReceivable | 707.00K | 10.14M | 21.33M | 22.38M |
| CashCashEquivalentsAndShortTermInvestments | 103.66M | 129.57M | 115.52M | 137.70M |
| CashAndCashEquivalents | 103.66M | 129.57M | 115.52M | 137.70M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -109.45M | -125.54M | -118.06M | -65.75M |
| RepaymentOfDebt | 0.00 | -1.00K | ||
| IssuanceOfDebt | 0.00 | 75.00M | 0.00 | |
| IssuanceOfCapitalStock | 59.39M | 91.95M | 25.00M | 0.00 |
| CapitalExpenditure | -4.96M | -20.17M | -44.96M | -55.22M |
| InterestPaidSupplementalData | 12.03M | 13.05M | 329.00K | 139.00K |
| EndCashPosition | 105.67M | 130.65M | 115.52M | 137.70M |
| BeginningCashPosition | 130.65M | 115.52M | 137.70M | 209.52M |
| EffectOfExchangeRateChanges | 1.50M | 2.44M | 674.00K | -1.28M |
| ChangesInCash | -26.48M | 12.69M | -22.86M | -70.54M |
| FinancingCashFlow | 54.53M | 84.02M | 95.20M | 1.71M |
| CashFlowFromContinuingFinancingActivities | 54.53M | 84.02M | 95.20M | 1.71M |
| NetOtherFinancingCharges | -4.86M | -7.94M | -5.03M | |
| InterestPaidCFF | -2.26M | 0.00 | ||
| ProceedsFromStockOptionExercised | 0.00 | 10.00K | 231.00K | 1.71M |
| CashDividendsPaid | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 59.39M | 91.95M | 25.00M | 0.00 |
| CommonStockIssuance | 59.39M | 91.95M | 25.00M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | 75.00M | -1.00K | |
| NetShortTermDebtIssuance | 0.00 | 75.00M | ||
| ShortTermDebtIssuance | 0.00 | 75.00M | ||
| NetLongTermDebtIssuance | 75.00M | -1.00K | ||
| LongTermDebtPayments | 0.00 | -1.00K | ||
| LongTermDebtIssuance | 75.00M | 0.00 | ||
| InvestingCashFlow | 23.48M | 34.03M | -44.96M | -61.72M |
| CashFlowFromContinuingInvestingActivities | 23.48M | 34.03M | -44.96M | -61.72M |
| NetOtherInvestingChanges | 28.43M | 54.21M | ||
| NetBusinessPurchaseAndSale | 0.00 | -6.50M | ||
| PurchaseOfBusiness | 0.00 | -6.50M | ||
| NetIntangiblesPurchaseAndSale | 54.21M | 0.00 | 0.00 | |
| SaleOfIntangibles | 54.21M | 0.00 | ||
| PurchaseOfIntangibles | 0.00 | |||
| NetPPEPurchaseAndSale | -4.96M | -20.17M | -44.96M | -55.22M |
| PurchaseOfPPE | -4.96M | -20.17M | -44.96M | -55.22M |
| OperatingCashFlow | -104.50M | -105.36M | -73.10M | -10.53M |
| CashFlowFromContinuingOperatingActivities | -104.64M | -105.37M | -73.22M | -10.53M |
| ChangeInWorkingCapital | 29.64M | -983.00K | 9.62M | 31.28M |
| ChangeInOtherWorkingCapital | 26.66M | -7.51M | -15.92M | -7.49M |
| ChangeInOtherCurrentLiabilities | 32.00K | -1.35M | 4.01M | -23.00K |
| ChangeInOtherCurrentAssets | -1.54M | -1.59M | 346.00K | 1.70M |
| ChangeInPayablesAndAccruedExpense | -3.22M | 1.95M | 16.35M | 21.46M |
| ChangeInAccruedExpense | -13.96M | -382.00K | 12.61M | 8.12M |
| ChangeInPayable | 10.74M | 2.33M | 3.74M | 13.35M |
| ChangeInAccountPayable | 10.74M | 2.33M | 3.74M | 13.35M |
| ChangeInPrepaidAssets | -1.33M | 2.69M | -329.00K | -1.08M |
| ChangeInInventory | -387.00K | 0.00 | ||
| ChangeInReceivables | 9.43M | 4.83M | 5.17M | 16.70M |
| ChangesInAccountReceivables | 6.33M | 9.97M | 1.03M | 16.39M |
| OtherNonCashItems | 1.30M | 545.00K | 218.00K | 2.74M |
| StockBasedCompensation | 25.19M | 27.72M | 28.62M | 20.78M |
| AssetImpairmentCharge | 0.00 | 1.15M | 0.00 | |
| DepreciationAmortizationDepletion | 12.68M | 13.72M | 8.60M | 7.87M |
| DepreciationAndAmortization | 12.68M | 13.72M | 8.60M | 7.87M |
| AmortizationCashFlow | 300.00K | 300.00K | 200.00K | |
| AmortizationOfIntangibles | 300.00K | 300.00K | 200.00K | |
| Depreciation | 12.38M | 13.42M | 8.40M | |
| OperatingGainsLosses | -25.52M | -63.49M | 9.45M | 6.36M |
| EarningsLossesFromEquityInvestments | 17.00K | 6.00K | 0.00 | 9.00K |
| NetForeignCurrencyExchangeGainLoss | 2.89M | -9.30M | 9.45M | 6.29M |
| GainLossOnSaleOfPPE | -28.43M | -54.20M | 0.00 | 56.00K |
| NetIncomeFromContinuingOperations | -147.79M | -84.03M | -129.62M | -79.56M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MGTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|